Emicizumab should be prescribed independent of immune tolerance induction.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes.Research and practice in thrombosis and haemostasis · 2023
   Article
2. Emicizumab in children: bleeding episodes and outcome before and after transition to Emicizumab.BMC pediatrics · 2022
   Article
3. Bispecific Antibodies and Advances in Non-Gene Therapy Options in Hemophilia.Research and practice in thrombosis and haemostasis · 2020
   Review
4. Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A.Frontiers in immunology · 2020
   Review
5. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.Drug design, development and therapy · 2020
   Review
6. Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors.Haemophilia : the official journal of the World Federation of Hemophilia · 2019
   Article
7. Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy.Molecular therapy. Methods & clinical development · 2019
   Review
8. Spotlight on emicizumab in the management of hemophilia A: patient selection and special considerations.Journal of blood medicine · 2019
   Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as